Aminophylline

Generic Name: Aminophylline

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₄N_₁₀O_₄

CAS Number: 317-34-0

Unique Ingredient Identifier: 27Y3KJK423

Background: Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD. The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply.

Indication: For the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Asthma, Bronchial Asthma, Bronchospasm, Chronic Bronchitis, Exacerbation of asthma

Clinical Trials

Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant

Not Applicable

Completed

Conditions: Function of Renal Transplant

Interventions: Drug: Aminophylline
Other: Theophylline drug levels
Drug: Placebo

First Posted Date: 2013-01-03

Last Posted Date: 2019-03-05

Lead Sponsor: Stanford University

Target Recruit Count: 50

Registration Number: NCT01759862

Locations: 🇺🇸
Lucile Packard Children's Hospital at Stanford, Stanford, California, United States

Rapid Acclimatization to Hypoxia at Altitude

Phase 1

Completed

Conditions: Physiological Function in Low Oxygen Environment

Interventions: Drug: Aminophylline+Methazolamide
Drug: Placebo
Drug: Methazolamide
Drug: Aminophylline

First Posted Date: 2012-10-05

Last Posted Date: 2014-10-24

Lead Sponsor: Colorado State University

Target Recruit Count: 41

Registration Number: NCT01702025

Locations: 🇺🇸
Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, United States

Aminophylline and Contrast Induced Nephropathy in Acute Myocardial Infarction

Phase 4

Completed

Conditions: Acute Kidney Injury

Interventions: Drug: Hydration plus N-acetylcisteine
Drug: Aminophylline

First Posted Date: 2012-05-09

Last Posted Date: 2012-10-30

Lead Sponsor: Ospedale Misericordia e Dolce

Target Recruit Count: 250

Registration Number: NCT01594489

Locations: 🇮🇹
Ospedale Misericordia e Dolce, Prato, Italy

Safety Evaluation of Aminophylline and Methazolamide

Phase 1

Completed

Conditions: Mountain Sickness

Interventions: Drug: Aminophylline
Drug: Methazolamide
Drug: Aminophylline and Methazolamide

First Posted Date: 2012-04-27

Last Posted Date: 2017-02-10

Lead Sponsor: Poudre Valley Health System

Target Recruit Count: 16

Registration Number: NCT01587027

Locations: 🇺🇸
Medical Center of the Rockies, Loveland, Colorado, United States

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers

Phase 1

Completed

Conditions: High Altitude Pulmonary Hypertension

Interventions: Drug: Aminophylline
Drug: Ambrisentan
Drug: Aminophylline plus ambrisentan

First Posted Date: 2012-02-10

Last Posted Date: 2014-01-16

Lead Sponsor: Thies Schroeder

Target Recruit Count: 18

Registration Number: NCT01530464

Locations: 🇺🇸
Duke Clinical Research Unit, Durham, North Carolina, United States

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Phase 4

Completed

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson